Calise Chris 4

What Happened

Chris Calise, a director of Coeptis Therapeutics Holdings, Inc. (COEP), acquired shares on February 11, 2026 by exercising 5,700 stock options at an exercise price of $10.56 per share (total cash paid $60,192). On the same date he also received a grant of 3,250 restricted shares issued at no cost as part of an option-exchange program.

These transactions are acquisitions (an option exercise and a restricted-stock grant), not sales.

Key Details

• Transaction dates: February 11, 2026; Form 4 filed February 13, 2026 (two days after the transactions).
• Option exercise: 5,700 shares at $10.56 per share (F1) — total exercise cost $60,192.
• Restricted shares: 3,250 shares granted at $0 in connection with an option-exchange program (F2).
• Beneficial ownership after the transactions: 105,556 shares total (this figure includes 49,500 shares owned by CJC Investment Trust and 47,106 shares issuable under currently exercisable warrants per F3).
• Footnotes: F1 = exercise price; F2 = restricted stock granted in exchange for surrendered underwater options; F3 = breakdown of trust-owned shares and issuable warrants.
• Filing timeliness: Form 4 filed Feb 13, 2026 (two days after the reported Feb 11 transactions) — appears to be timely.

Context

• The reporting shows an option exercise (exercise -> acquisition of shares) and a restricted-stock award issued in exchange for underwater options. No immediate sale or cashless disposition of the exercised shares was reported on the Form 4.
• Restricted-stock grants issued for surrendered underwater options are a common corporate action to replace low-value options and do not by themselves indicate an intent to buy or sell in the open market.